Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Class H (HK:6990) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced its agreement to subscribe for two structured deposits from BOCOM totaling RMB370 million, with the transactions being subject to reporting requirements under Chapter 14 of the Listing Rules. The first deposit, agreed upon on April 22, 2024, was for RMB170 million with a minimum annualized return of 1.65%, while the second, on July 5, 2024, was for RMB200 million. These investments are principal-guaranteed with floating returns linked to the price of Shanghai Gold, highlighting a strategic move by the company to manage its financial assets.
For further insights into HK:6990 stock, check out TipRanks’ Stock Analysis page.